Enterprise Value
2.181B
Cash
228.6M
Avg Qtr Burn
N/A
Short % of Float
13.21%
Insider Ownership
4.94%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
APOKYN® (apomorphine hydrochloride injection) Details Advanced Parkinson’s disease (PD) | Approved Quarterly sales | |
Gocovri (Amantadine) Details Dyskinesia (Parkinson's disease) | Approved Quarterly sales | |
Namzaric Details Alzheimer's Dementia | Approved Quarterly sales | |
Osmolex ER (amantadine) Details PD (Parkinson's Disease) | Approved Quarterly sales | |
MYOBLOC® (rimabotulinumtoxinB) Details Cervical Dystonia Sialorrhea | Approved Quarterly sales | |
Qelbree (viloxazine hydrochloride) Details Attention deficit hyperactivity disorder (ADHD) | Approved Quarterly sales | |
Oxtellar XR® (oxcarbazepine) Details Epilepsy | Approved Quarterly sales | |
Gocovri (Amantadine) Details Parkinson's disease for OFF episodes | Approved Quarterly sales | |
Trokendi XR® (topiramate) Details Prophylaxis of migraine | Approved Quarterly sales | |
XADAGO (safinamide) Details Parkinson's disease | Approved Quarterly sales | |
SPN-830 Details Parkinson's disease, Brain disease | NDA Resubmission | |
SPN-820 Details Treatment Resistant Depression, Mental health | Phase 2 Data readout | |
SPN-817 Details Epilepsy | Phase 2 Data readout |